European Journal of Clinical Pharmacology 1990-01-01

Pharmacokinetics of a valpromide isomer, valnoctamide, in healthy subjects.

M Bialer, A Haj-Yehia, N Barzaghi, F Pisani, E Perucca

Index: Eur. J. Clin. Pharmacol. 38(3) , 289-91, (1990)

Full Text: HTML

Abstract

The pharmacokinetics of a single 400 mg oral dose of valnoctamide (VCD) has been investigated in seven healthy, adult, male volunteers. VCD was not biotransformed rapidly to its corresponding acid valnoctic acid (VCA), unlike its isomer valpromide (VPD). It had a mean residence time of 13.2 h and a terminal half-life of 9.3 h. Throughout the study, only low plasma levels of VCA could be detected. Thus, unlike VPD, which is a pro-drug of the corresponding acid, (valproic acid, VPA). VCD appears to act as a drug in its own right, and it does not undergo similar hydrolysis. The pharmacokinetic difference may account for the different pharmacological activities of the two isomers.

Related Compounds

  • Valnoctamide

Related Articles:

Structure activity relationship of human microsomal epoxide hydrolase inhibition by amide and acid analogues of valproic acid.

2000-02-01

[Pharm. Res. 17(2) , 216-21, (2000)]

A comparative electrographic analysis of the effect of sec-butyl-propylacetamide on pharmacoresistant status epilepticus.

2013-02-12

[Neuroscience 231 , 145-56, (2013)]

Amidic modification of valproic acid reduces skeletal teratogenicity in mice.

2004-02-01

[Birth Defects Res. B Dev. Reprod. Toxicol. 71(1) , 47-53, (2004)]

Polycomb homologs are involved in teratogenicity of valproic acid in mice.

2004-11-01

[Birth Defects Res. A Clin. Mol. Teratol. 70(11) , 870-9, (2004)]

Identification of early-responsive genes correlated to valproic acid-induced neural tube defects in mice.

2005-04-01

[Birth Defects Res. A Clin. Mol. Teratol. 73(4) , 229-38, (2005)]

More Articles...